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Abstract: The Convention on Biological Diversity (CBD), adopted in 1992 and entered into force at 
the end of 1993, established a global regime on access to genetic resources (GR) and sharing of 
benefits arising from their utilization (Access and Benefit Sharing (ABS) regime). Its protocol—the 
Nagoya Protocol (NP)—which entered into force 21 years later in 2014, clears up some 
terminological ambiguities of the Convention, clarifies and develops several procedural and 
instrumental elements of the regime, and obliges States Parties to implement some of its provisions, 
including the core instrument of the regime: the bilateral ABS agreement between users and 
providers of GR, that became a condition for obtaining access to the resource. However, scholars 
who analyzed the ABS regime as well as its official bodies find, and sometimes deplore, the small 
number of ABS agreements concluded so far, under the CBD as under the NP. This paper has two 
objectives: First, to assess the effectiveness of the ABS regime implemented by the CBD and the NP 
on the basis of its central instrument: the ABS agreements concluded between users and providers 
of GR. The aim is to accurately document the number of ABS agreements concluded since the entry 
into force of the regime. To our knowledge, such a counting that is neither piecemeal nor has an 
estimate yet been produced. To do so, I combine several sources, including first hand data collected 
from the official information agencies—the National Focal Points (NFP)—of each of the States 
Parties to the NP. Second, I provide a critical summary of the existing explanations of the low 
number of ABS agreements concluded and I evaluate the corresponding causal mechanisms, relying 
on the results I obtained regarding the number of permits and agreements.  
Keywords: Access and Benefit Sharing; Convention on Biological Diversity; Nagoya Protocol;  
ABS agreements 
 
1. Introduction 
1.1. Context 
Over the past 40 years, enormous advances have been made in life sciences disciplines. Since the 
1970s, it has been possible to act directly on the genetic material contained in the nucleus of the cells 
of living organisms [1]. DNA became a source of value, a resource, the genetic resource (GR). Almost 
simultaneously the decline of biodiversity (in other words the genetic diversity among and within 
species) has been recognized as a major environmental issue of global scope [2]. 
For almost half a century, GR are the subject of intense debates and rivalries which mainly 
concern (1) their appropriation through material and intellectual property rights (IPRs); (2) the 
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necessity to conserve them and use them sustainably; and (3) the effects of their manipulation 
through genetic engineering technics. 
Numerous public policies, on all jurisdictional and institutional levels, were implemented to 
address public problems arising from the utilization of GR. Among these policies, the Convention on 
Biological diversity (CBD) aims to regulate the uses of biodiversity. One of the objectives of this treaty 
is the implementation of an Access and Benefit Sharing (ABS) mechanism. In other words, through 
the CBD, the international community wanted to establish a global regime regulating the access to 
GR which are used to perform scientific researches so as to enable the fair sharing of the benefits that 
may arise from those research activities. Although important efforts have been undertaken to make 
such a regime effective, culminating with the adoption of a binding protocol to the CBD—the Nagoya 
Protocol (NP)—in 2010, important and numerous reservations were expressed by scholars [3–7], 
researchers dealing with GR [4,8–10], as well as by countries which provide GR [1,4,11–13] on the 
regime’s capacity to achieve its objectives. The purpose of this article is to empirically verify how 
those doubts about the effectiveness of the ABS regime are confirmed by the results the regime 
obtained so far, based on its core instrument: the ABS agreements concluded between users and 
providers of GR. At a time when the majority of States Parties to the CBD or NP are still in the process 
of adopting the national ABS legislations that will implement the regime, it seems both scientifically 
relevant and useful in terms of public policy to compare theoretical knowledge of ABS as well as 
practical experiences of it with empirical data on its functioning on a global scale. 
1.2. The Genetic Resource and Its Utilization 
Genetic materials are directly used through three sets of biotechnological techniques [14]: 
 Selective breeding and artificial selection, which is the selection of organisms with useful 
properties by producing targeted mutations on their genomes or by crossing directly their 
genomes (cell fusion, molecular markers, etc.). 
 Genetic engineering, which is the modification of genomes by removing genetic material or by 
adding sequences from other organisms, which belong or not to the same species. 
 Synthetic biology, which is the artificial creation of biological systems (naturally occurring or 
not) by adding artificial DNA sequences to a minimal natural genetic ‘frame’ or by assembling 
segments of artificial DNA to build a functional system. 
The technical capacities of manipulating genetic material have made it a resource in its own 
right. The benefit flows arising from GR are exploited through the production systems of 
biotechnology (A series of colors is usually used to identify several branches of biotechnology: green 
for agricultural and environmental biotech, red for pharmaceutical and other medical related biotech, 
blue for marine and coastal biotech, yellow for food and nutrition biotech, and white for biomaterial 
and other industrial process biotech). 
It should also be mentioned that numerous indirect utilizations of the genetic materials of 
organisms are constantly performed. Traditional breeding of cows or the extraction of essential oils 
from plants belong to these indirect uses of genetic properties, which in other words are the 
utilization of the material results of the biochemical processes induced by the genetic material. I 
return to this issue at the end of Section 1.4. 
1.3. Material and Intellectual Property Rights over Genetic Resources 
The biotechnology sector emerged in the 1970s and, with it, the will to protect the new 
corresponding inventions [1,15]: From the first successes of each of these techniques, intellectual 
property rights (IPRs) on newly extracted, isolated, purified, modified, or artificially created GR have 
been claimed and, more or less rapidly depending on the case, granted [16–19]. If the material 
property over organisms (a herd of sheep, a plant nursery, etc.) is as old as the domestication of plants 
and animals, it has traditionally been assumed that no IPRs over living matter can be granted. Most 
IPR legislations require, for protection to be granted, that the IPR is claimed over an invention and 
not over the simple discovery of something already existing. Yet, biological matter, as a manifestation 
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of Nature, cannot be invented, but only discovered. The living was thus considered to be part of a 
common heritage of humanity, which cannot be appropriated by IPRs [1,15,20,21]. However, the 
molecular biology techniques mentioned above started to challenge this doctrine. The direct 
manipulation of GR changed their status, from product of Nature to product of the ingenuity of the 
human mind and therefore qualified them as possible candidate for protection by IPRs. During the 
year 1980, a Supreme Court decision (The US Supreme Court decision in Diamond v. Chakrabarty’s 
case, which legalized the patentability of a genetically modified bacterium.) and the adoption of the 
Bayh-Dole Act (The Bayh-Dole Act is a patent law passed by US Congress, that allows publicly-
funded research teams to patent their discoveries (including on living matter) and encourages them 
to build partnerships with the private sector) [3], both in the United States, made the obtainment of 
IPRs over living beings possible. The general principle of this legal reversal is the following: once the 
natural GR has been genetically modified, it can be patented, provided that the modification in 
question is new, applicable within an industrial process, and can be considered as an invention 
[16,19]. Since then, patenting has become a widespread practice, first in the United States, then in 
Europe [3,16,18,19]. 
1.4. Global Regulation of Genetic Resources Utilization 
Concerns about the appropriation of GR through IPRs met environmental ones in the 1980s, as 
discussions started on the necessity to adopt a global framework regulating biodiversity utilizations. 
At the time, the environment had already become a political issue and the erosion of biodiversity a 
public problem of global importance [2]. Southern States, many of whom were newly independent 
at that time, contested the GR’s status as a common heritage of humanity. They considered it to be 
an insidious form of colonialism led by the northern agrochemicals and pharmaceuticals industries 
[1,13,20,21]. Rather paradoxically, the nationalist demands of GR suppliers were coupled with users 
countries’ will to support their biotechnology industry: the suppliers countries’ request of national 
sovereignty over GR located within their territories was perfectly acceptable to actors of the 
biotechnology field, as they saw it as an opportunity to extend the international IPR regime to living 
matter [13]. In a nutshell, the deal was to exchange national sovereignty over GR for the possibility 
to claim IPRs on these resources. 
Thus, an ad hoc Working Group of Technical and Legal Experts (who became the so called 
Intergovernmental Negotiating Committee) established by the United Nations Environment 
Program (UNEP) was able to submit a draft convention for an international regulatory regime on the 
uses of all living natural resources. The final text was accepted in 1992 during the Nairobi Conference 
for the Adoption of the Agreed Text of the Convention on Biological Diversity. The Convention on 
Biological Diversity (CBD) was adopted the same year at the United Nations Conference on 
Environment and Development (the Rio “Earth Summit”) and entered into force in December 1993. 
The scope of the regime established by the Convention on Biological Diversity (CBD) extends to 
the genetic material of plants, animals and microorganisms, which means [22] “(…) any material of 
plant, animal, microbial or other origin containing functional units of heredity”. The regime pursues 
a triple objective: to conserve genetic diversity, make its uses sustainable, and ensure an equitable 
sharing of the benefits flows derived from them. The legal concept of access and benefit sharing (ABS) 
refers to this last objective. With ABS, the request of Southern States on property rights over GR was 
integrated to the regime by granting to each State a sovereign right over the GR situated on its 
territory. Concretely, this means that the material ownership of GR belongs to the States and that they 
have sole competence to decide under what conditions access to ‘their’ GR can be granted and 
resulting benefits shared [1,21]. 
The regime is based on two categories of instruments to achieve its objectives. First, in order to 
conserve biodiversity and encourage sustainable utilization of biological and genetic resources, CBD 
States Parties are invited to develop and implement plans, strategies or programs. Second, regarding 
equitable sharing of the benefits, private law contracts are the core instrument. They formalize the 
arrangements concluded between a GR supplier state and a particular user by stipulating which GRs 
are used, for which purposes, and how any corresponding benefits could be shared. In this 
Resources 2017, 6, 11  4 of 14 
 
perspective, equity, conservation and sustainability are supposed to be linked by a “virtuous” cyclical 
process: monetary and non-monetary benefits shared by the users with the providers of the initial 
GR are (at least partially) used to support conservation and sustainability, through the funding of 
corresponding measures. Additionally, provider states and their local populations are encouraged to 
preserve their genetic capital, as the regime makes it a source of income. 
Several alternative ABS regimes have been implemented. These regimes are distinguished by 
two main dimensions: the degree of cooperation between the actors and the nature of property rights 
on GR (which determines the conditions of access, use and exchange). Significant examples include 
the introduction of common pools of (free access to the resources and multilateral sharing of the 
benefits) seeds in order to ensure food security. The International Treaty on Plant Genetic Resources 
for Food and Agriculture (ITPGRFA), adopted by the Food and Agriculture Organization of the 
United Nations (FAO) in 2001 and into force since 2004, established such a common pool of GR, called 
the Multilateral System (MLS). The MLS was elaborated in accordance with the CBD provisions but 
it differs from the Convention on several points. It is legally binding and aims at the conservation 
and sustainable use of food crops of extreme importance to global food security as well as the 
equitable sharing of benefits derived from these GR. It applies to 35 varieties of food crops and 29 
forage varieties, which make up more than 80% of the caloric intake coming from plants in the human 
diet [18]. These GRs are co-owned, improved, and traded almost everywhere in the world. States 
Parties must grant unrestricted access to these varieties. The monetary and non-monetary benefits 
are shared among all States Parties through a common fund and the corresponding knowledge and 
information are collected in a common database. The facilitating exchange system proposed by the 
MLS has been successful in terms of the volume of material exchanged [18]. 
Originally, the ambition of the international community was the adoption of an “umbrella 
convention”. In other words, a treaty able to absorb and consolidate the numerous existing regional 
and global conventions dealing with the different aspects of biological diversity. The members of the 
Working Group of Technical and Legal Experts finally concluded that such an “umbrella convention” 
was both legally and technically impossible to set up [23]. As a results, the CBD took the form of a 
“framework convention”, an intentionally loose and flexible treaty [24] that features the founding 
principles of the cooperation between concerned States Parties in the specific field of biodiversity. 
The idea behind an instrument like the framework convention is to stagger the establishment of 
norms: first, the framework convention establishes the legal bases and principles; then, States Parties 
have the authority to implement them independently through national legislation [25]. 
A framework conventions is equivalent to the convention-protocol approach: after agreeing on 
relatively vague core principles, States Parties continue to meet regularly in order to adopt more 
specific and binding collective rules on particular subjects related to the original convention. Their 
formal manifestation is often a protocol to this convention [24]. 
This is typically the case with CBD: one year after the Convention entered into force, States 
Parties have begun to meet periodically within the context of the Conferences of the Parties (COP) 
for further negotiations. The implementation of the CBD through national ABS legislations in States 
Parties proved to be particularly difficult regarding its third objective of fair benefit sharing. The 
cooperation between Parties was not optimal as user countries had not assisted providers in this task 
[11]. Concerns about the possible free use of GR despite the adoption of the Convention incited the 
States Parties to implement a set of binding rules dealing with the ABS elements of the CBD. In 2002, 
in Cancun (Mexico), several megadiverse countries set up the Group of Like-Minded Megadiverse 
Countries (GLMMC) (Bolivia, Brazil, China, Colombia, Costa Rica, Democratic Republic of the 
Congo, Ecuador, Ethiopia, Guatemala, India, Indonesia, Iran, Kenya, Madagascar, Malaysia, Mexico, 
Peru, Philippines, South Africa, and Venezuela). The origins of this group of countries go back to 
1998, when Conservation International, a US non-profit environmental NGO established a list of the 
countries harboring the majority of Earth’s species, the 17 megadiverse countries (Australia, Brazil, 
China, Colombia, Democratic Republic of the Congo, Ecuador, India, Indonesia, Madagascar, 
Malaysia, Mexico, Papua New Guinea, Peru, Philippines South Africa, United States, and Venezuela). 
This group is the political expression of the interests of this minority of Southern States accounting 
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for the majority of the existing GR. During the negotiations of the NP, the GLMMC has been a 
megaphone for the developing countries, defending strong views on the ABS related issues (like 
compliance measures from user States). It took 10 COPs to agree on a binding protocol to the 
Convention—the Nagoya Protocol (NP)—adopted in 2010 [1]. 
States Parties to the NP are required to adopt a clear national ABS legislation. Provider countries 
have to put procedures into place to regulate access GR situated on their territory. Access to the 
resource is granted through an access permit whose deliverance is conditioned by the obtaining of 
the Prior Informed Consent (PIC) of the Competent National Authority (CNA, the official body 
entitled to regulate ABS according to the corresponding national legislation) or additional providers 
(local community, individual, etc.) if applicable. Basically, PIC embodies the consent of the provider 
on the basis of the information given by the user regarding the research he intends to conduct 
(description of the GR and the sampling sites, quantity of samples, duration of the access requested, 
etc.). Once a PIC is obtained, user and provider have to agree on the Mutually Agreed Terms (MAT). 
The MAT constitute a bilateral private law contract that establishes the conditions of access, uses of 
the resource and the sharing of benefits (commercial or non-commercial research purposes, amount 
of monetary benefits to be shared, payment terms, etc.). As a user country, a State Party has to ensure 
itself that GRs used through R&D programs on their territory were obtained in accordance with the 
provisions of the providers’ ABS legislation. If that is not the case, they must take compliance 
measures. 
Regarding the scope of the NP, it is based on the same definition of GR as the CBD but clarifies 
however [26] that: “‘Utilization of genetic resources’ means to conduct research and development on 
the genetic and/or biochemical composition of genetic resources”. This is considered to be an 
important improvement as it means that ABS rules also applies to derivatives, the variety of 
(bio)chemicals compounds extracted from GR (enzymes, flavonoids, alkaloids, etc.) [11]. Therefore, 
by enlarging the scope of the regime to the biochemical compounds from GR but that do not 
themselves contain functional units of heredity, a wide range of R&D became concerned with ABS 
requirements. Only research and developments activities though fall within the scope of ABS, which 
means that for example the supply of a plant GR to extract an already known active compound will 
not be regulated by the NP, as such activities do not encompass research and development. 
As of November 2016, the CBD has 198 States Parties. Since the adoption of the NP in 2010, 79 
States Parties to the CBD signed and ratified it, thus becoming States Parties to the NP. Half of those 
79 countries have a national ABS legislation in force. Regarding States Parties to the CBD only, 17 
countries implemented a national ABS legislation. This latter group of countries includes the 
members of the Andean Community (Bolivia, Colombia, Ecuador, and Peru) who have implemented 
an alternative ABS regime based not on the NP but on the Decision No. 391 Establishing the Common 
Regime on Access to Genetic Resources adopted in 1996. 
In short, there are four relevant groups of States Parties in regard to the CBD and the NP: 
(I) States Parties to the NP: 79 countries 
(II) States Parties to the NP with a ABS legislation in force: 22 countries 
(III) States Parties to the CBD: 119 countries 
(IV) States Parties to the CBD with a ABS legislation in force: 17 countries 
The following figure details this typology of countries (I used the data published by the Access 
and benefit-sharing Clearing-house (ABSCH): https://absch.cbd.int. ABSCH is the official platform 
for collecting information on ABS. I also used information collected through our survey and the 
following sources: [27]; several documents found on The ABS Capacity Development Initiative’s 
website (http://www.abs-initiative.info), a multi-donor initiative supporting stakeholders from 
Africa, Caribbean and the Pacific for the implementation of national ABS.): 
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2. Purposes of the Study 
The main purpose of this contribution is to test the two explanations I found in the literature, 
which try to explain the poor results of the ABS regime in terms of so far issued access permits and 
concluded ABS agreements. To do so, I first used empirical data to confirm these poor results. Then, 
I used the same data as well as additional information obtained through interviews conducted with 
experts and other relevant second-hand information to test the validity of the causal mechanisms 
assumed by the two explanations. 
2.1. Estimation of the Number of Permits Issued and ABS Agreements Concluded 
Key publications on the ABS regime implemented through the CBD and its protocol note its 
difficulties, so far, in achieving its objectives, as very few ABS agreements have been concluded and 
consequently very few benefits have been shared [2,3,6–8,28–30]. 
However, to our knowledge, there is not any accurate counting of either access permits granted 
or ABS agreements concluded since the entry into force of the CBD or the NP. I found piecemeal 
information indicating that the number is small but no systematic inventory. I consider that providing 
reliable data about access permits and ABS agreements is essential to analyze the concrete functioning 
of the regime. This is the core aim of our contribution. To get a picture that includes as many countries 
as possible, I combine two sources of data. 
2.1.1. Data Collected from an Online Survey 
In September 2016, I sent a survey by e-mail to contact persons of the National Focal Points (NFP) 
(NFP are official agencies that provide information on national ABS procedures and relevant 
stakeholders.) listed on the Access and Benefits Sharing Clearing-House (ABSCH) (ABSCH is the 
official information portal established by the NP. Parties have to submit relevant data to the ABSCH 
which has a role of information-hub). I submitted it to all NFPs of the States Parties to the NP (82 
countries) and to the 16 countries that are Parties only to the CBD and have a ABS legislation in force 
(Afghanistan, Australia, Bolivia, Brazil, Brunei, Colombia, Costa Rica, Ecuador, Malaysia, Morocco, 
Nicaragua, Panama, Polynesia, Salomon Islands, Singapore, Thailand, and Venezuela). 
It contained three questions (the last one was asked only to the States Parties to the NP): 
 How many ABS agreements have been concluded in your country? 
 How many access permits to GR have been issued in your country? 
 If possible, could you indicate the proportion of agreements/permits that have been 
concluded/issued before and after your country became a State Party to the NP? 
I could have focused exclusively on States Parties having an ABS legislation in force in their 
national legislative arsenal, as they are the only one where access permits and agreements can be 
found a priori. Nevertheless, I considered I had to verify if States Parties still lacking such a legislation 
had already collected data about GR accessed in their countries or used tools similar to permits or 
agreements but eventually based on other legislation (like any environmental one) to regulate the 
access to their GR. 
On the 96 surveys I sent (79 States Parties to the NP and 17 States Parties to the CBD only), I 
received only 23 answers (response rate = 23.95%). Among the States Parties to the NP, I received 
answers from Bhutan, Burundi, Cambodia, Comoros, Croatia, Czech Republic, Ivory Coast, the 
European Union, Finland, Germany, Guyana, India, Norway, Rwanda, Slovakia, Spain, Switzerland, 
Togo, and UK. Among the States Parties to the CBD, I received answers from Costa Rica, Ecuador, 
Malaysia, and Venezuela. I did not expect such a low response rate, especially because I took pains 
to send the survey specifically to the individuals in charge of the NFPs. It is likely that the States 
Parties without an ABS legislation in force do not have data to share. This could explain the result. 
Concerning the States Parties belonging to the groups II and III (Figure 1) that did not answer, some 
of them could have considered these data sensitive and preferred not to communicate on that matter. 
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Figure 1. Groups of States Parties to the CBD and the NP. 
2.1.2. Data Collected from Secondary Sources 
To compensate the low response rate to our survey, I used several secondary sources, including 
scientific papers, previously conducted interviews, and annual reports of competent national 
authorities. As I could not search the relevant information for all the 76 countries I did not receive 
answers from, I focused on the countries having an ABS legislation into force and those hosting the 
most GR. I found relevant additional data about Australia, Bolivia, Brazil, Colombia, Cuba, 
Indonesia, Mexico, Peru, and South Africa. Finally, with the first and second-hand data, I covered 
33.33% of the 96 States Parties I wanted to get information about. Although, it is still a low coverage 
rate, our sample is composed by almost all the potentially most important provider countries, where 
the regime is the most likely to show results in terms of agreements and permits. I consider that the 
representativeness of this sample allows us to draw some lessons from the results obtained regardless. 
2.1.3 The Access and Benefits Sharing Clearing-House as Source of Data 
As mentioned in Section 1.4, the ABSCH is the official information portal of the ABS regime 
established by the NP. According to [31], States Parties shall notify the ABSCH about the issuance of 
a Certificate of Compliance as evidence of the decision to grant PIC and of the establishment of MAT. 
[32,33] state that Parties shall also notify the Secretariat about the NFP and CNA they designated and 
that the Secretariat shall make those information available through the ABSCH. Finally, [34] states 
that “Without prejudice to the protection of confidential information, each Party shall make available 
to the Access and Benefit-sharing Clearing-House any information required by this Protocol, as well 
as information required pursuant to the decisions taken by the Conference of the Parties serving as 
the meeting of the Parties to this Protocol”. Thus, by consulting the ABSCH’s website, one should be 
able to know what the requirements regarding ABS are in any State Party, whom to contact to get 
more information (NFP), which agency has the competency to issue the PIC and conclude the MAT 
(CNA) as well as information about the Certificates of Compliance, namely the PICs and MATs that 
have been concluded so far. 
The ABSCH was indeed very useful to obtain an updated list of the States Parties to the CBD or 
NP having a national ABS legislation in force and an updated list of the NFP I wanted to send my 
survey to. Unfortunately, the platform turned out to be disappointing to get data about access 
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permits, ABS agreements or any other evidence of access to GR regulated by the regime. Only four 
States Parties published such data (although they are required to): Guatemala (one case), Mexico (one 
case), South Africa (two cases), and India (46 cases), the latter being by far the best performer in terms 
of sharing this information. 
2.2. Critical Review of the Current Existing Explanations of the Numbers of Permits and Agreements 
The second aim of this contribution is to discuss the existing explanations of the poor results of the 
ABS regime in terms of access permits and agreements concluded that can be found in the literature. 
To discuss them, I relied on the numbers collected (Table 1), on several scientific contributions and on 
data from interviews conducted with an agronomist, head of a (public) research team working on plant 
improvement and a professor of genetics as well as data collected from presentations (and following 
unformal discussions) given at a conference (in Switzerland) specially organized to inform non-
commercial academic researchers working with GR about ABS requirements. 
Scholars and officials mention several reasons that can be distinguished between two distinct 
causal mechanisms: 
(1) Very few contracts have been concluded because the implementation of national ABS laws by 
States Parties is incomplete or dissuading potential users to request access to GR: 
o Only a small minority of States Parties to the Convention or Protocol have been able to put 
in place the corresponding national legislations. This is notably due to a lack of technical 
expertise, lack of sufficient budget, lacking strong enough government structures and 
political support, local social conflict, and conflict over ownership of GR [35]. 
o Among the few states that have succeeded in adopting ABS legislation, several have 
developed fragmented and ambiguous legal frameworks with poorly defining 
competencies, multiplying PIC to be obtained from different stakeholders and on the basis 
of different laws. Some existing legislations require long, cumbersome, and complicated 
procedures to establish MATs or obtain access [6,12]. They also do not offer sufficiently 
distinct procedures between access requests for basic and commercial researches [4,12]. The 
adoption of such restrictive legislations is explained by the expectations among provider 
countries that they will get money from the ABS mechanism and their will to put an end to 
the free and abusive utilization of “their” GR [4]. The lack of willingness by user countries 
to put measures into place to monitor compliance with the provisions of supplier countries 
is also mentioned as one of the factors that have made provider countries particularly cautious 
and pushed them to adopt restrictive access conditions to their GR [11,12]. Indeed, once the GR 
has left the provider’s territory, the latter has no way to monitor that the downstream process 
of R&D complies with the provisions of the corresponding ABS agreement. The insurance that 
user countries would monitor downstream process in that regard was therefore crucial for 
provider States. That was, and still is, a source of major disappointment for them and they 
responded to it by adopting restrictive ABS provisions [4,11]. 
(2) Very few contracts have been concluded because of a lack of demand for GR by potential users 
o The high demand for GR that was anticipated during the 1990s has not been confirmed. The 
entry into force of the CBD is already 22 years old and progress in the field of biotechnology 
has profoundly modified the research processes as well as the research strategies of the 
pharmaceutical, agrochemical, food, and cosmetic firms. On one hand, it became possible 
to probe more deeply the GR research teams already have in their immediate environment 
or in the numerous ex situ collections they can freely access [8]. For example, in the 
agrochemical and seed sectors, the major actors of the industry use mergers and 
acquisitions to extend their collections of GR. The seed industry has been consolidating 
strongly over the last 30 years. The numerous small actors of the market (and most 
importantly the varieties, genes or technologies they possess through IPRs) are bought by 
a few multinationals through mergers and acquisitions [10,36–38]. As a result, in the early 
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2000s, emerged the so-called ”Big Six” group composed of Syngenta, Bayer, Monsanto, 
DuPont, Dow, and BASF. These consolidated groups are active in both the agrochemical, 
seed, and pharmaceutical sectors. For the seed market in particular, the five largest groups 
hold more than 45% of the market share in terms of sales volumes [36]. Consolidation has 
a direct effect on plant GR exchanges as well as, although to a lesser extent, on 
bioprospection for wild GR. Indeed, this industrial strategy of both vertical and horizontal 
integration aims among other things to obtain IPRs (mostly patent) via the purchase of the 
small companies that have those IPRs over biotechnology technics, traits (genes), 
organisms, etc. [9,10]. Consolidation thus proportionally increases the catalog of GR at the 
disposal of the “Big Six”, whether these GR are protected by a plant breeders right or a 
patent. Consequently, these ‘giant’ actors escape the ABS regime, as they are not (or to a 
minimal extend) requesting access to foreign GR. 
o On the other hand, high throughput screening and combinatorial chemistry make it 
possible to generate whole libraries of molecules to be tested on various biological targets 
without having to rely on the diversity of natural compounds and in a faster and cheaper 
way than the latter [9]. As a result, there is a decline of interest for the search for exotic GR—
the so called “green gold”—since the 1990s [3,29]. 
o Moreover, if GR are used through biotechnology technics, only a minute amount of the 
resource is needed to conduct R&D program (sequencing, amplification, eventually 
artificial reproduction, etc.), which makes the monitoring of access difficult and the 
resupply unnecessary. Metagenomics represent an “extreme” aspect of this evolution as it 
makes it possible to extract genetic material from complex environmental samples, without 
having to deal with the organisms carrying it [9]. Finally, because of scientific advances, the 
interest for GRs has shifted to micro-organisms. This evolution has several decreasing 
effects on demand for access to GR: the origin of micro-organisms is far more difficult to 
identify, one can easily access microbes through vast and freely accessible collections or by 
collecting samples in his own backyard [9]. 
Those two distinct general causal mechanisms explaining the poor success of the ABS regime in 
terms of permits granted and agreements concluded do not exclude each other. The lack of interest 
showed by users in accessing GRs can be due to both alternative technical R&D options and 
discouraging ABS procedures. The pharmaceutical industry for example has mentioned the 
uncertainties around ABS requirements as one of the causes that led to a decline in its natural products 
research in the last decade [4]. Nevertheless, the implications of the two causal mechanisms are 
fundamentally different with respect to the functioning of the regime and the possibility to improve it. 
Indeed, if natural GRs are becoming a significantly less interesting raw material for R&D activities in 
pharmaceutical and other biotechnology sectors, no matter how the ABS legislations could be improved 
and the corresponding procedures facilitated, the regime lacks both the activities it is supposed to 
regulate and the source of its redistributive mechanism. That is why an evaluation of the causal effect 
of the two causal mechanisms (1. implementation difficulties and 2. scientific/technological 
alternatives) is useful to assess the capacity of the CBD-PN’s regime to achieve its objectives. 
The data concerning the numbers of access permits and ABS agreements I have been able to 
obtain are not sufficient to determine, among the complex combination of factors simultaneously 
working in the two causal mechanisms, which one is likely to produce the most important effect. 
Nevertheless and although they are incomplete (as data from several countries are missing), they 
give some first useful information for the discussion of the causal mechanisms mentioned above. 
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3. Results 
The following tab shows the data I obtained from our survey and secondary sources: 
Table 1. Access permits issued and ABS agreements concluded. 
 Access Permits Granted ABS Agreements Concluded 
 Commercial 
Non-
Commercial 
Commercial Non-Commercial 
Commercial ABS 
Agreements/Year 
States Parties to the Nagoya Protocol with ABS Legislation in Force 
India  
(2006–2016) 
91  
(53 since Party to the NP) 
14  
(2 under NP) 
0 1.4 
Guyana  
(2000–2014) 
344 0 0 
Cuba  
(2008–2016) 
200 5 0 0.6 
Peru  
(2009–2013) 
180 0 10 2.5 
South Africa  
(2008–2015) 
17 33 n.i 4.7 
Indonesia  
(2000–2015) 
5286 n.i n.i n.i 
States Parties to the Nagoya Protocol 
18 other state 
parties 1 
0 0 0 0 
States Parties to the CBD with ABS Legislation in Force 
Costa Rica  
(2004–2015) 50 333 3 45 0.2 
Ecuador  
(2011–2016) 
n.i 1 39 0.2 
Venezuela  
(1996–2016) 
39 
22  
(13 since the current 
ABS law entered 
into force in 2009) 
57  
(27 since the current 
ABS law entered 
into force in 2009) 
1.1 
Brazil  
(2004–2013) 
n.i 
1057  
(2010–2012) 
103 n.i 11.4 
Bolivia  
(2000–2005) 
n.i 
2  
(50-60 requests) 
8 0.4 
Colombia  
(2003–2013) 
n.i 1 
89  
(199 requests) 
0.1 
Mexico  
(1996–2011) 
4283 n.i n.i n.i 
Australia  
(2006–2015) 
3 276 3  n.i 
1 Bhutan, Burundi, Cambodia, Comoros, Croatia, Czech Republic, Ivory Coast, the European Union, 
Finland, Germany, Norway, Rwanda, Slovakia, Spain, Switzerland, Togo, and UK. 
3.1. Analysis of the Results 
3.1.1. Accuracy of the Estimation 
Considering the relatively poor response rate to our survey, I first of all have to acknowledge 
that our estimation of the number of access permits issued and ABS agreements concluded is not as 
accurate as expected. There are 39 countries with a functioning ABS legislation and I obtained data 
from 14 of them (35.8%). Among these 14 countries, 5 answered to the survey (India, Guyana, Costa 
Rica, Venezuela and Ecuador), and 9 either published the relevant data or answered to previous 
scholars [4,15,27,39,40]. 
Nevertheless, I cover a high proportion of the concerned megadiverse countries except China 
and the Philippines. Therefore, I can reasonably consider that, except the two countries mentioned, 
it is unlikely that I missed an additional State Party with an ABS legislation in force and with an 
important amount of permits and agreements. 
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3.1.2. General Comments 
On the basis of the numbers at our disposal, it is clear that very few ABS agreements have been 
concluded so far. Between 1996 and 2015, 217 such agreements for commercial research and 248 for 
non-commercial research have been concluded. On average, out of the 14 countries with an ABS 
legislation in force, 2.05 ABS agreements for commercial researches have been concluded per year. 
Those results confirm therefore the consensus I found in the literature. 
Regarding the implementation of national ABS legislations, I observe a significantly more 
important ratio of countries with such a legislation currently into force among the States Parties to 
the NP compared with the States Parties to the CBD only. That confirms the intuitive reasoning 
according to which there is a less important will among the latter to adopt a functioning ABS 
framework. In addition, with the notable exception of Switzerland, all the other 38 States Parties 
having an ABS law into force belong to the category of provider States. Those countries include 12 
out of the 17 megadiverse countries. Out of the current 20 members of the Like-Minded Megadiverse 
Countries organization, 14 are States Parties to CBD and NP or NP only, with an ABS legislation into 
force. Those 14 GLMMC members represent 35.9% of the 39 States Parties having successfully 
implemented an ABS legislation. Therefore, it has to be pointed out that a significant number of the 
existing ABS legislations have been elaborated and adopted by countries known for their restrictive 
position on ABS. That also confirms the strong will of this group to regulate the access to their GR. 
3.1.3. Analysis of the First Explanatory Causal Mechanism in the Light of the Results 
Unsurprisingly, all the States Parties to the NP without an operating ABS legislation that have 
answered to our survey indicated that neither permits have been issued nor ABS agreements 
concluded as no legal basis has been established so far. This indicates, in accordance with the first 
explanatory causal mechanism, that the lack of ABS legislations could explain the poor results of the 
regime in terms of permits and agreements. This proposition is of course rather trivial. 
In regards to the explanation relying on the attributes of existing ABS legislations, the results do 
not support any interpretation of the corresponding causal claims. Only an in-depth analysis of the 
relevant ABS legislations would enable to evaluate the efficiency and legal certainty of their 
procedures. Only then would it be possible to verify if clearer and more certain procedures would 
produce better results in terms of permits and agreements. However, I can mention that, on one hand 
some of these national ABS frameworks are already relatively old (more than 10 years for Brazil, 
Costa Rica, Cuba, India, Mexico, and the members of the Andean community and more than 8 years 
for South Africa) and that several have already been evaluated and improved [27,35]. Most of the 
existing ABS legislations provide for legal certainty, clarity, and transparency of domestic 
requirements as well as non-arbitrary rules and procedures for accessing to GR [35]. On the other 
hand, in practice, procedures to obtain PIC and MAT are generally not precisely described [35]. In 
addition, 11 out of the 14 States Parties with an ABS legislation I obtained data about are GLMMC 
members, a stakeholder’s group known for its nationalist and restrictive positions on ABS. Actually, 
several of the corresponding ABS frameworks (Brazil, Indonesia, and Colombia) have already been 
evaluated as restrictive, cumbersome, and finally dissuading the potential users [4,35] while the Costa 
Rican one has been considered as more clear, certain, and flexible [4,35]. Based on our results, it 
appears Costa Rica has so far concluded a relatively important number of ABS agreements (although 
the majority for non-commercial purpose) and as well as 383 access permits. That could indicates that 
the legal certainty and the facilitation of the ABS procedures could produce better results in terms of 
permits and agreements. 
3.1.4. Analysis of the Second Explanatory Causal Mechanism in the Light of the Results 
According to the results, users of GRs whether for commercial or non-commercial research 
activities, seem to have been relatively uninterested in GR bioprospecting for GRs in provider 
countries. Here again, based strictly on the obtained numbers, it is unclear whether this lack of 
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interest is primarily due to complicated and uncertain legal frameworks (that users prefer to avoid 
dealing with) or, if it is to research strategies which do not require natural in situ GR. 
It deserves to be noted that the results include almost all of the most biodiverse countries. According 
to the ranking produced by Mongabay (https://news.mongabay.com/2016/05/top-10-biodiverse-
countries/), out of the 13 most biodiverse countries in the world, 11 appear in our results. As the potentially 
most important provider countries have so far concluded few agreements although they have 
implemented ABS legislations for several years (and even if those legislations suffer from weaknesses and 
can reasonably be considered as rather restrictive (see Section 3.1.2), the importance of their GR for the 
biotechnology industry can be put into serious question. 
Our results also show that there is a relatively high number of access permits issued in 
comparison with the agreements concluded but more importantly, a significantly higher proportion 
of issued permits and concluded agreements for non-commercial purposes compared with 
commercial ones. This suggests that the private sector indeed showed little interest in prospecting 
GRs compared with basic research. It therefore would be relevant to pursue in the assessment of the 
hypothesis that the ABS regime implemented through the CBD and its protocol does not reach the 
actors of private research (those who are supposed to engage in research activities for commercial 
purposes) in the field of biotechnology, which is its main target group. As mentioned in Section 2.2, 
these actors have access to as many GRs as they need without engaging in the ABS process because 
they either have access to their own in or ex situ collections or can rely on alternative research technics 
(bioinformatics, combinatorial chemistry combined with high throughput screening, etc.). On the 
contrary, actors from the public research, who cannot easily ‘escape’ from the ABS regime by using 
their own GR or by adopting alternative research strategies see therefore their activities more 
regulated by the regime. Several researchers working in public entities expressed a feeling of being 
overregulated and hindered from performing traditional and frequent tasks like requesting or 
sampling GR or exchanging them. This was also confirmed during the interviews I conducted. 
3.2. Research Perspectives 
This contribution shows some promising possibilities for further research. For example, after 
conducting an in-depth analysis of the content of two national ABS legislations, one considered as 
facilitating the ABS and the corresponding procedures and the other as restrictive and cumbersome 
for the potential users, to collect data on the agreements concluded under these legislations. Such 
research would certainly enlighten the impact of the ABS legislations provisions on the functioning 
of the regime. Another promising research perspective would be going deeper into the analysis of 
the (few) ABS agreements concluded so far. Such a qualitative analysis could shed light on the 
characteristics of the users of GRs (private or public research). Additionally, collecting data on the 
commercial utilizations of GRs (in particular on the corresponding patents and products placed on 
the market) would be necessary to determine to what extent the assumed relative disinterest for 
natural GRs is real or if the utilizations of genetic material remains important but evolved in such a 
way that the CBD-NP ABS regime is not adapted to regulate them.  
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